Scholarlink

Background <p>Up to 15% of NSCLC cases arise in never-smokers, and an additional subset arises in light smokers. Data on these groups in the Middle East are limited. Therefore, we compared the clinicopathological features, survival, and molecular alterations in never and light smokers with stage IV NSCLC treated at a tertiary center in Jordan.</p> Methods <p>We retrospectively reviewed data from January 2015 to December 2023. Never-smokers were defined as those who had smoked &lt; 100 lifetime cigarettes, and light smokers as those who had smoked &lt; 5 pack-years. Survival rates and prognostic variables were estimated using Kaplan–Meier analysis and univariate Cox models.</p> Results <p>Among 190 patients (median age 54 years), 159 were never smokers and 31 were light smokers. Never smokers were mainly female (69.8%), whereas light smokers were predominantly male (58.1%). Brain metastases were common (55.8%). EGFR mutations occurred in 80.6% of light smokers versus 58.5% of never-smokers. High PD-L1 expression (≥ 50%) was observed in 30% of both groups. One-year OS was 61% in never-smokers and 54.8% in light smokers. EGFR-negative tumors showed better 3- and 5-year OS than EGFR-positive tumors in both smoking strata. No clinical or molecular variables reached statistical significance in the univariate Cox analysis.</p> Conclusion <p>Never and light smokers with stage IV NSCLC displayed distinct features. The high prevalence of actionable EGFR alterations underscores the importance of comprehensive molecular testing. Region-specific data should inform precision oncology strategies and the design of prospective trials targeting non-traditional risk groups.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival patterns and mutation profiles in never- and light-smokers with stage IV NSCLC

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月22日

查看全文
  • Kholoud Alqasem,
  • Sakhr Alshwayyat,
  • Salsabeel Aljawabrah,
  • Karam Maraqa,
  • Alaa BanyAmer,
  • Aysheh Al-Khawaja,
  • Bayan Sheikh Ali,
  • Shahed Al-atiyat,
  • Rahaf Turab,
  • Rana Elmalahi,
  • Ala’aldin Eqleem,
  • Sumaiah Alnaimat,
  • Ahmad BanyAmer,
  • Marwa Alshatti,
  • Zaid Omari,
  • Mohammad Abu Shattal

摘要

Background

Up to 15% of NSCLC cases arise in never-smokers, and an additional subset arises in light smokers. Data on these groups in the Middle East are limited. Therefore, we compared the clinicopathological features, survival, and molecular alterations in never and light smokers with stage IV NSCLC treated at a tertiary center in Jordan.

Methods

We retrospectively reviewed data from January 2015 to December 2023. Never-smokers were defined as those who had smoked < 100 lifetime cigarettes, and light smokers as those who had smoked < 5 pack-years. Survival rates and prognostic variables were estimated using Kaplan–Meier analysis and univariate Cox models.

Results

Among 190 patients (median age 54 years), 159 were never smokers and 31 were light smokers. Never smokers were mainly female (69.8%), whereas light smokers were predominantly male (58.1%). Brain metastases were common (55.8%). EGFR mutations occurred in 80.6% of light smokers versus 58.5% of never-smokers. High PD-L1 expression (≥ 50%) was observed in 30% of both groups. One-year OS was 61% in never-smokers and 54.8% in light smokers. EGFR-negative tumors showed better 3- and 5-year OS than EGFR-positive tumors in both smoking strata. No clinical or molecular variables reached statistical significance in the univariate Cox analysis.

Conclusion

Never and light smokers with stage IV NSCLC displayed distinct features. The high prevalence of actionable EGFR alterations underscores the importance of comprehensive molecular testing. Region-specific data should inform precision oncology strategies and the design of prospective trials targeting non-traditional risk groups.